Related Experiment Video
Updated: Aug 10, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Consolidation therapy without maintenance for acute non-lymphoblastic leukaemia
M M Roberts1, C A Juttner, R W Blunden
1Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA.
The Medical Journal of Australia
|February 15, 1988
Summary
Brief intensive chemotherapy for acute non-lymphoblastic leukaemia achieved remission rates comparable to long-term treatments. This approach offers a potentially effective alternative for prolonging remission and improving cure rates in leukaemia patients.
Area of Science:
- Oncology
- Hematology
- Clinical Trials
Background:
- The optimal chemotherapy regimen for acute non-lymphoblastic leukaemia (ANLL) remains uncertain.
- Current treatment strategies vary significantly, ranging from single consolidation courses to extended maintenance and intensification therapies.
Purpose of the Study:
- To evaluate the efficacy of a brief, intensive chemotherapy regimen for ANLL.
- To compare outcomes of this regimen against established long-term chemotherapy protocols.
Main Methods:
- A cohort of 72 ANLL patients received brief intensive therapy.
- The regimen included daunorubicin, cytosine arabinoside, and thioguanine, with no maintenance therapy.
- Patients were followed for a minimum of two years.
Main Results:
- A complete remission rate of 67% was achieved.
- The median duration of remission was 11 months.
- 23% of patients achieving remission remained disease-free for three years or longer.
Conclusions:
- Brief intensive chemotherapy demonstrates comparable efficacy to long-term chemotherapy in ANLL.
- This regimen represents a viable alternative for ANLL treatment, potentially improving remission duration and cure rates.
